NASDAQ · OCUP
Healthcare · Biotechnology
$1.17
Down-$0.16 (-12.03%)
Updated Aug 22, 2026, 5:05 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
OCUP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning OCUP.
OCUP research
Company profile and research snapshot.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2024 | Canaccord Genuity | Buy | — |
| Aug 15, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2024 | Canaccord Genuity | Buy | — |
| May 13, 2024 | Canaccord Genuity | Buy | — |
| May 13, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 23, 2024
Ocuphire Pharma announced the acquisition of Opus Genetics, a gene therapy company for inherited retinal diseases. The combined company will be renamed Opus Genetics and focus on gene therapy pipeline, while seeking a partner to advance the late-stage diabetic retinopathy program.
GlobeNewswire Inc. · Sep 30, 2024
Ocuphire Pharma announced the publication of full results from two Phase 3 clinical trials evaluating the safety and efficacy of Phentolamine Ophthalmic Solution 0.75% for the treatment of pharmacologically-induced mydriasis. The results demonstrated rapid reversal of pupil dilation with a favorable safety profile.
GlobeNewswire Inc. · Sep 6, 2024
Ocuphire Pharma has initiated the VEGA-3 Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia. The company also expects top-line data from the LYNX-2 Phase 3 trial in the first quarter of 2025.
GlobeNewswire Inc. · Jun 6, 2024
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company’s lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OCUP.
No results
No recent SID articles mention OCUP.
